TABLE 4.
Association between TMAO, CMPF, and risk of kidney replacement therapy1
| KRT initiation, HR [95%CI] | ||
|---|---|---|
| ln CMPF | ln TMAO | |
| Crude | 0.74 [0.67,0.82] | 1.78 [1.46,2.16] |
| Model 1 | 0.82 [0.73,0.91] | 1.11 [0.88,1.40] |
| Model 2 | 0.79 [0.71,0.89] | 1.04 [0.83,1.31] |
| Model 3 | 0.80 [0.71,0.90] | 1.01 [0.81,1.27] |
1
n = 737. Crude model: ln TMAO + ln CMPF. Model 1: adjusted for age, sex, eGFR, and ACR. Model 2: model 1 + country, diabetes, preexisting cardiovascular disease, Charlson comorbidity index, diastolic blood pressure, systolic blood pressure, and malnutrition (SGA <5). Model 3: model 2 + albumin, phosphate, and hemoglobin. ACR, albumin creatinine ratio; CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropionate; eGFR, estimated glomerular filtration rate; KRT, kidney replacement therapy; SGA, subjective global assessment; TMAO, trimethylamine N-oxide.